Extended safety and efficacy studies of a live attenuated double leucine and pantothenate auxotroph of Mycobacterium tuberculosis as a vaccine candidate

Vaccine

Volumn 29, Issue 29-30, 2011, Pages 4839-4847

  Sampson, Samantha L ^a,e   Mansfield, Keith G ^b   Carville, Angela ^b   Magee, D Mitchell ^c,f   Quitugua, Teresa ^c,g   Howerth, Elizabeth W ^d   Bloom, Barry R ^a   Hondalus, Mary K ^a,d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d UNIVERSITY OF GEORGIA   (United States)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^f ARIZONA STATE UNIVERSITY   (United States)

^g National Biosurveillance Integration Center   (United States)

Author keywords

Auxotroph; Guinea pig; Rhesus macaque; SIV; Tuberculosis; Vaccine

Indexed keywords

BCG VACCINE; LEUCINE; MYCOBACTERIUM TUBERCULOSIS VACCINE; MYCOBACTERIUM VACCINE; PANTOTHENIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUXOTROPHY; BACTERIAL STRAIN; BLOOD ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GUINEA PIG; HEMATOLOGY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; LONG TERM CARE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SURVIVAL RATE; TUBERCULOSIS;

EID: 79960649514     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.066     Document Type: Article

References (49)

1. Dye C, Williams BG. The population dynamics and control of tuberculosis. Science 2010;328(5980):856-61.
2. World Health Organization. Global tuberculosis control: a short update to the 2009 report. Geneva: World Health Organization; 2009.
3. Mansoor N, Scriba Thomas F J., de Kock M, Tameris M, Abel B, Keyser A, et al. HIV-1 infection in infants severely impairs the immune response induced by Bacille Calmette Guérin vaccine. The Journal of Infectious Diseases 2009;199(7):982-90.
4. Hesseling AC, Johnson LF, Jaspan H, Cotton MF, Whitelaw A, Schaaf HS, et al. Disseminated bacille Calmette-Guerin disease in HIV-infected South African infants. Bulletin of the World Health Organization 2009;87(7):505-11.
5. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006;367(April (9517)):1173-80.
6. Baily GV. Tuberculosis prevention Trial, Madras. Indian Journal of Medical Research 1980;72(Suppl.):1-74.
7. Behr MA, Wilson MA, Gill WP, Salamon H, Schoolnik GK, Rane S, et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 1999;284:1520-3.
8. Sirisanthana V. Complication of Bacillus Calmette-Guerin (BCG) vaccine in HIV-infected children. Journal of Infectious Disease and Antimicrobial Agents 1995;2(2):63-7.
9. Rezai MS, Khotaei G, Mamishi S, Kheirkhah M, Parvaneh N. Disseminated Bacillus Calmette-Guerin infection after BCG vaccination. Journal of Tropical Pediatrics 2008;54(6):413-6.
10. Global Advisory Committee on Vaccine Safety. Revised BCG vaccination guidelines for infants at risk for HIV infection. Weekly Epidemiological Record 2007;82:181-96.
11. World Health Organization. WHO recommendations on the diagnosis of HIV infections in adults and children. World Health Organization; 2010.
12. Kaufmann SH. Future vaccination strategies against tuberculosis: thinking outside the box. Immunity 2010;33(October (4)):567-77.
13. Kaufmann SHE, Hussey G, Lambert P-H. New vaccines for tuberculosis. Lancet 2010;375:2110-9.
14. Grode L, Seiler P, Baumann S, Hess J, Brinkmann V, Nasser Eddine A, et al. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. Journal of Clinical Investigation 2005;115(9):2472-9.
15. Hoft DF, Blazevic A, Abate G, Hanekom WA, Kaplan G, Soler JH, et al. A new recombinant Bacille Calmette Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. The Journal of Infectious Diseases 2008;198(10):1491-501.
16. http://www.stoptb.org/wg/newvaccines/documents.asp. Stop TB Partnership Working Group on New TB Vaccines; 2009.
17. Larsen MH, Biermann K, Chen B, Hsu T, Sambandamurthy VK, Lackner AA, et al. Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates. Vaccine 2009;27(34):4709-17.
18. Sampson SL, Dascher CC, Sambandamurthy VK, Russell RG, Jacobs WR, Bloom BR, et al. Protection elicited by a double leucine and pantothenate auxotroph of Mycobacterium tuberculosis in guinea pigs. Infection and Immunity 2004;72(5):3031-7.
19. Verreck FAW, Vervenne RAW, Kondova I, Kralingen KWv, Remarque EJ, Braskamp G, et al. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in Rhesus macaques. PLoS One 2009;4(4):e5264.
20. Mansfield KG, Veazey RS, Hancock A, Carville A, Elliott M, Lin K-C, et al. Induction of disseminated Mycobacterium avium in Simian AIDS is dependent upon Simian immunodeficiency virus strain and defective granuloma formation. American Journal of Pathology 2001;159(2):693-702.
21. Cline AN, Bess JW, Piatak Jr M, Lifson JD. Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. Journal of Medical Primatology 2005;34:303-12.
22. Ravn P, Demissie A, Eguale T, Wondwosson H, Lein D, Amoudy HA, et al. Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis. Journal of Infectious Diseases 1999;179(March (3)):637-45.
23. Lifson J, Nowak M, Goldstein S, Rossio J, Kinter A, Vasquez G, et al. The extent of early viral replication is a critical determinant of the natural history of Simian immunodeficiency virus infection. Journal of Virology 1997;71(12):9508-14.
24. Freeman LM, Mansfield KG, Goldin B, Woods M, Gualtieri L, Li W, et al. Bodycomposition changes in the Simian immunodeficiency virus-infected juvenile rhesus macaque. Journal of Infectious Diseases 2004;189(June (11)):2010-5.
25. Brown CR, Czapiga M, Kabat J, Dang Q, Ourmanov I, Nishimura Y, et al. Unique pathology in Simian immunodeficiency virus-infected rapid progressor macaques is consistent with a pathogenesis distinct from that of classical AIDS. Journal of Virology 2007;81(11):5594-606.
26. Letvin N, Mascola J, Sun Y, Gorgone D, Buzby A, Xu L, et al. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 2006;9(312), 5779-1533.
27. Liu J, O'Brien KL, Lynch DM, Simmons NL, La Porte A, Riggs AM, et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2008;457(7225):87-91.
28. Freeman LM, Mansfield KG, Lackner AA, Naumova EN, Gorbach SL. Survival and failure to thrive in the SIV-infected juvenile rhesus monkey. Journal of Acquired Immune Deficiency Syndromes 1999;22(October (2)):119-23.
29. Chen ZW, Shen Y, Zhou D, Simon M, Kou Z, Lee-Parritz D, et al. In vivo Tlymphocyte activation and transient reduction of viral replication in macaques infected with Simian immunodeficiency virus. Journal of Virology 2001;75(May (10)):4713-20.
30. Croix D, Capuano S, Simpson L, Falert B, Fuller C, Klein E, et al. Effect of mycobacterial infection on virus loads and disease progression in Simian immunodeficiency virus-infected rhesus monkeys. AIDS Research and Human Retroviruses 2000;16(17):1895-908.
31. Zhou D, Shen Y, Chalifoux L, Lee-Parritz D, Simon M, Sehgal P, et al. Mycobacterium bovis bacille Calmette-Guerin enhances pathogenicity of Simian immunodeficiency virus infection and accelerates progression to AIDS in macaques: a role of persistent T cell activation in AIDS pathogenesis. Journal of Immunology 1999;162:2204-16.
32. Shen Y, Shen L, Sehgal P, Zhou D, Simon M, Miller M, et al. Antiretroviral agents restore Mycobacterium-specific T-cell immune responses and facilitate controlling a fatal tuberculosis-like disease in Macaques coinfected with Simian immunodeficiency virus and Mycobacterium bovis BCG. Journal of Virology 2001;75(September (18)):8690-6.
33. Sharpe SA, McShane H, Dennis MJ, Basaraba RJ, Gleeson F, Hall G, et al. Establishment of an aerosol challenge model of tuberculosis in rhesus macaques, and an evaluation of endpoints for vaccine testing. Clinical and Vaccine Immunology 2010;17(8):1170-82.
34. Langermans JAM, Andersen P, van Soolingen D, Vervenne RA, Frost PA, van der Laan T, et al. Divergent effect of bacillus Calmette-Guerin (BCG) vaccination on Mycobacterium tuberculosis infection in highly related macaque species: implications for primate models in tuberculosis vaccine research. Proceedings of the National Academy of Sciences of the United States of America 2001;98(20):11497-502.
35. Abu-Raddad LJ, Sabatelli L, Achterberg JT, Sugimoto JD, Longini IM, Dye C, et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proceedings of the National Academy of Sciences of the United States of America 2009;106(33):13980-5.
36. Cardona PJ, Asensio JG, Arbues A, Otal I, Lafoz C, Gil O, et al. Extended safety studies of the attenuated live tuberculosis vaccine SO2 based on phoP mutant. Vaccine 2009;27(April (18)):2499-505.
37. Martin C, Williams A, Hernandez-Pando R, Cardona PJ, Gormley E, Bordat Y, et al. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 2006;24(April (17)):3408-19.
38. Sambandamurthy VK, Derrick SC, Hsu T, Chen B, Larsen MH, Jalapathy KV, et al. Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. Vaccine 2006;24(September (37-39)):6309-20.
39. Kamath A, Fruth U, Brennan M, Dobbelaer R, Hubrechts P, Ho M, et al. New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development. Vaccine 2005;23(29):3753-61.
40. Walker KB, Brennan MJ, Ho MM, Eskola J, Thiry G, Sadoff J, et al. The second Geneva Consensus: recommendations for novel live TB vaccines_. Vaccine 2010;28(11):2259-70.
41. Capuano SV, Croix DA, Pawar S, Zinovik A, Myers A, Lin PL, et al. Experimental Mycobacterium tuberculosis infection of cynomolgus macaques closely resembles the various manifestations of human M. tuberculosis infection. Infection and Immunity 2003;71(10):5831-44.
42. Kita Y, Tanaka T, Yoshida S, Ohara N, Kaneda Y, Kuwayama S, et al. Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model. Vaccine 2005;23(17-18):2132-5.
43. Langermans J, Doherty T, Vervenne R, Laan T, Lyashchenko K, Greenwald R, et al. Protection of macaques against infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Vaccine 2005;23(21): 2740-50.
44. Reed SG, Coler RN, Dalemans W, Tan EV, DeLa Cruz EC, Basaraba RJ, et al. Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proceedings of the National Academy of Sciences of the United States of America 2009;106(7):2301-6.
45. Sugawara I, Sun L, Mizuno S, Taniyama T. Protective efficacy of recombinant BCG Tokyo (Ag85A) in rhesus monkeys (Macaca mulatta) infected intratracheally with H37Rv Mycobacterium tuberculosis. Tuberculosis 2009;89(1):62-7.
46. Cheynier R, Gratton S, Halloran M, Stahmer I, Letvin N, Wain-Hobson S. Antigenic stimulation by BCG vaccine as an in vivo driving force for SIV replication and dissemination. Nature Medicine 1998;4(4):421-7.
47. Garcia-Contreras L, Wong YL, Muttil P, Padilla D, Sadoff J, DeRousse J, et al. Immunization by a bacterial aerosol. Proceedings of the National Academy of Sciences of the United States of America 2008;105(12):4656-60.
48. Wong YL, Sampson S, Germishuizen WA, Goonesekera S, Caponetti G, Sadoff J, et al. Drying a tuberculosis vaccine without freezing. Proceedings of the National Academy of Sciences of the United States of America 2007;104(February (8)):2591-5.
49. Richter CB, Lehner NDM, Henrickson RV. Primates. In: Fox JG, Cohen BJ, Loew FM, editors. Laboratory Animal Medicine. Orlando: Academic Press; 1984. p. 298-383.